Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amoxicillin-clavulanic acid in hospitalized patients with COPD exacerbation
NL-OMON22557Suspended
- Sponsor
- Dr. P. D. L. P. M. van der Valk
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amoxicillin + clavulanate in chronic obstructive pulmonary disease (COPD), sponsored by Dr. P. D. L. P. M. van der Valk. Primary endpoint: Sputum amoxicillin concentration at day 3. Started Oct 2011; status: suspended.
02
Drugs
amoxicillin + clavulanate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON22557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22557.